MSLN-CD3 Bispecific Binding Agent for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic antibodies targeting mesothelin (MSLN) have shown medium to low efficacy, necessitating the development of more effective therapeutic molecules that can specifically bind to MSLN and potentially enhance T-cell engagement for cancer treatment.
Innovation Solution
A binding agent comprising an antigen binding region that specifically binds to MSLN, utilizing variable domains with defined amino acid sequences to compete with existing antibodies or bind to membrane-restricted regions of MSLN, potentially in combination with a second antigen binding region targeting CD3ε to redirect T-cells to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic antibodies targeting MSLN are used, then MSLN binding is achieved, but treatment efficacy remains medium to low
Solution Approach 1:
The patent applies local quality by directing T-cell engagement specifically to MSLN-expressing tumor cells through the dual-specific binding agent. The CD3 binding domain recruits T-cells while the MSLN binding domain provides tumor cell specificity, creating a localized immunotherapeutic effect at the tumor site rather than systemic activation. This resolves the contradiction by maintaining binding specificity for MSLN while improving treatment efficacy through localized T-cell mediation.
Solution Approach 2:
The patent uses T-cells as an intermediary to mediate the therapeutic effect. Instead of the antibody directly killing tumor cells, the dual-specific binding agent recruits T-cells (via CD3 binding) which then exert cytotoxic effects on MSLN-expressing cells. This intermediary mechanism transforms the medium efficacy of direct antibody binding into enhanced therapeutic efficacy through T-cell-mediated immunity, while preserving MSLN binding specificity.
2Reliability
If dual-specific binding agents are developed to enhance T-cell engagement, then treatment efficacy improves, but molecular complexity increases
Solution Approach 1:
The patent merges two antibody specificities (MSLN binding and CD3 binding) into a single dual-specific binding agent molecule. This consolidation creates a unified therapeutic molecule that can simultaneously engage both the tumor antigen and T-cells, improving treatment efficacy through coordinated action while managing molecular complexity by integrating functions into one structure rather than requiring separate molecules.
Solution Approach 2:
The dual-specific binding agent exhibits multi-functionality by simultaneously performing antigen recognition (MSLN binding), T-cell recruitment (CD3 binding), and T-cell activation. This universal molecule replaces what would otherwise require multiple separate therapeutic agents, improving efficacy through coordinated functions while the modular design helps manage the inherent molecular complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binding agent enhances T-cell engagement and cytotoxicity towards MSLN-expressing cancer cells, such as mesothelioma, ovarian, and pancreatic cancers, by specifically targeting membrane-restricted MSLN epitopes, potentially increasing treatment efficacy.
Implementation Method 1
a binding agent comprising an antigen binding region that (a) binds to an epitope of MSLN recognized by an antibody
Implementation Method 2
enhances T-cell engagement and cytotoxicity towards MSLN-expressing cancer cells
Data Source
AI summary
The present disclosure provides MSLN binding agents in the monospecific and multispecific formats, including bispecific MSLN×CD3 binding proteins, and related compositions and methods of use.